FTC Blocks Teva From Reverse-Payment Patent Deals

Drug Industry Daily
The Federal Trade Commission has reached a global settlement resolving three antitrust lawsuits against Teva Pharmaceuticals subsidiaries. Once approved by the courts, the settlement will bar the drugmaker from reverse-payment patent deals that restrict patient access to less expensive generics.

To View This Article:


Subscribe To Drug Industry Daily